What Multispan does

Multispan, Inc. is a privately held, founder-led biotechnology company headquartered in Hayward, California, specializing in cell-based assay products and services for G protein-coupled receptor (GPCR) drug discovery. Founded in 2004 by Helena Mancebo, who continues to serve as CEO and President, the company operates with 11-50 employees and serves pharmaceutical companies, biotechnology firms, and academic research institutions engaged in GPCR-targeted drug discovery programs.

The company's core offering is the proprietary MULTISCREEN platform, which integrates cell engineering, assay development, and high-throughput screening (HTS) into a single consolidated workflow. Multispan maintains a catalog of more than 600 clonally-derived stable cell lines and over 2,000 assay tools and reagents, supported by proprietary technologies including Beta-Arrestin Sensor Technology for studying GPCR signaling bias and High Expressing Cell Technology for enhanced receptor expression. Its assay portfolio includes TR-FRET cAMP No Wash kits, Calcium No Wash kits, division-arrested assay-ready cells, membrane preparations, and specialized screening panels including a 32-GPCR Safety Panel, a 231-GPCR comprehensive panel, and a recently launched 50-GPCR+ Safety Panel. Service offerings span custom cell-based and kinase assay development, HTS, compound profiling, safety pharmacology, GPCR antibody profiling, CRISPR cell engineering, and a success-based plate subscription for SAR screening.

Multispan operates a hybrid revenue model combining catalog product sales (cell lines, assay kits, membranes, reagents) with fee-for-service drug discovery contracts. The company uses a sales-led, consultation-based go-to-market approach targeting B2B customers, with pricing conducted via quote-based consultation requests rather than public price listing. The business has been financed primarily through two early-stage rounds from Amkey Ventures totaling $1.1 million and has operated for over 20 years, indicating a lean, largely self-sustaining operating posture.

Name

Multispan

Legal name

Multispan, Inc.

Website

https://multispaninc.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Multispan is a Hayward, California-based biotechnology company specializing in GPCR drug discovery tools and services. It provides over 600 stable cell lines, proprietary assay kits, and custom high-throughput screening services to pharmaceutical, biotechnology, and academic research customers.

Ownership category

akta.pro rank

Product category

GPCR Cell-Based Assays and Reagents

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

akta.pro secondary industries

Cell-Based & Potency Assays (Bioassays) (HLAGADAH), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• GPCR cell lines
• Cell-based assays
• Drug discovery services
• High throughput screening
• Stable cell line development

Headquarters

HQ city

Hayward

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Cell Line Products: Sale of HTS-ready stable cell lines, division-arrested cells, and membrane preparations. Catalog includes over 600 clonally-derived stable cell lines and 2000+ assay tools and reagents.
2. Assay Kits and Reagents: Sale of assay kits including TR-FRET cAMP and Calcium No Wash assay kits along with other reagent products for GPCR research.
3. Drug Discovery Services: Fee-for-service offerings including custom cell-based assay development, custom kinase assay development, HTS screening, compound profiling, safety pharmacology, GPCR antibody profiling, and CRISPR cell line engineering services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Multispan develops, manufactures, and sells GPCR-focused cell-based assay products and provides drug discovery services to pharmaceutical, biotechnology, and academic research customers. Its catalog includes more than 600 clonally-derived HTS-ready stable cell lines, 2,000+ assay tools and reagents (including TR-FRET cAMP and Calcium No Wash assay kits, division-arrested cells, and membrane preparations), complemented by fee-for-service offerings such as custom cell-based and kinase assay development, high-throughput screening, compound profiling, GPCR antibody profiling, and CRISPR cell line engineering, all delivered through the proprietary MULTISCREEN™ platform.

Product overview

Multispan is a biotechnology company specializing in GPCR (G-protein coupled receptor) drug discovery products and services. The company offers an integrated platform centered around the MULTISCREEN brand, which includes over 600 HTS-ready stable cell lines, 2000+ assay tools and reagents, and comprehensive screening services. The portfolio consists of three main product categories: (1) MULTISCREEN cell products including stable cell lines, division-arrested cells, and membrane preparations; (2) MULTISCREEN assay kits including TR-FRET cAMP and Calcium No Wash assay kits; and (3) drug discovery services including custom assay development, high-throughput screening, compound profiling, and CRISPR cell engineering. The company also offers proprietary technologies such as Beta-Arrestin Sensor Technology and High Expressing Cell Technology, along with specialized GPCR panels (32-GPCR Safety Panel, 231-GPCR Panel) for off-target liability assessment.

Differentiator

Problem solved

Functional benefit

Brands

• MULTISCREEN™: Proprietary technology platform for cell-based assays, stable cell lines, assay kits, and HTS solutions for GPCR drug discovery.

Products and services

• MULTISCREEN HTS-Ready Stable Cell Lines Clonally-derived stable cell lines engineered to express GPCRs and other drug targets, validated for high-throughput screening applications; over 600 clones available. Sold to pharmaceutical, biotechnology, and academic research customers.
• MULTISCREEN GPCR HTS Assay Kits Ready-to-use assay kits including TR-FRET cAMP 1.0 No Wash Assay Kit and Calcium 1.0 No Wash Assay Kit for measuring intracellular signaling in GPCR drug discovery, compatible with 96-well, 384-well, or higher density microplates.
• MULTISCREEN Division-Arrested Cells Assay-ready frozen cells that are division-arrested for immediate use in screening, providing consistent results without the need for ongoing cell culture maintenance.
• MULTISCREEN Membrane Preparations Cell membranes prepared from GPCR-expressing stable cell lines for radioligand binding and other membrane-based assays, available for over 500 GPCR targets.
• Cell Proliferation Assay Kits Assay kits for measuring cell proliferation in drug discovery applications, complementary to Multispan's GPCR-focused product lines.
• Custom HTS-Ready Cell Line Development Bespoke development of stable cell lines tailored to specific drug discovery needs, engineered with validated potency assay performance.
• Custom Cell-Based Assay Development Development of custom cell-based assays for target validation and compound screening, with protocols optimized for each client's specific requirements.
• Drug Discovery Services and HTS High-throughput screening services using Multispan's validated cell lines and assay platforms to identify and profile compound activity for drug discovery clients.
• Compound Profiling Services Comprehensive compound profiling across multiple signaling pathways including safety pharmacology panels to assess off-target liability for drug discovery programs.
• GPCR Antibody Profiling Services Screening and characterization of antibodies targeting GPCRs using flow cytometry and functional cell-based assays to identify cross-reactivity and support antibody therapeutic development.
• CRISPR Cell Line Engineering Services CRISPR-based gene editing services to create custom cell lines with specific genetic modifications for assay-ready cell line development.
• Custom Kinase Cell-Based Assay Development Custom assay development services specifically for kinase targets using cell-based approaches for drug discovery screening.
• Cell Banking and Cell Scale-up Services Cell banking services for secure storage and scale-up of cell lines to support long-term research and commercial needs.

Quantifiable outcome

• Advancement of discovery efforts to candidate selection in less than 9 months
• +2 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Eurofins DiscoverX: Eurofins DiscoverX (formerly DiscoverX) is a direct competitor in cell-based assays, particularly through its PathHunter β-arrestin recruitment platform and enzyme fragment complementation technology. Like Multispan, it supplies GPCR cell lines, assay kits, and profiling services to pharma and biotech for drug discovery.
• BPS Bioscience: BPS Bioscience develops cell lines, assay kits, and recombinant proteins for drug discovery, including extensive GPCR and kinase offerings. It is a close comparable to Multispan in catalog-driven cell line and assay products serving pharma and academic researchers.
• Innoprot: Innoprot specializes in cell-based assay services and stable cell line development for drug discovery, including GPCR targets. It mirrors Multispan's integrated offering of catalog cell lines, custom cell engineering, and screening services for pharmaceutical and academic clients.

Broad incumbents

• Charles River Laboratories: Charles River is a large CRO offering a broad portfolio of discovery and safety assessment services that includes cell-based assays, HTS, and safety pharmacology. It competes with Multispan for outsourced GPCR-related drug discovery work but as part of a much wider service catalog spanning biologics, preclinical, and manufacturing.
• Thermo Fisher Scientific: Thermo Fisher provides laboratory reagents, cell lines, and assay kits across drug discovery through its Life Sciences Solutions segment. Its GPCR and cell biology reagents and services overlap with Multispan's catalog but sit within a much larger portfolio spanning instruments, consumables, and CRO services (PPD).
• Revvity (formerly PerkinElmer Life Sciences): Revvity offers assay kits, detection platforms, and reagents including cell-based signaling assays relevant to GPCR research. It overlaps with Multispan's TR-FRET and cell-based assay offerings but as part of a broader life sciences and diagnostics portfolio serving pharma, academic, and diagnostic customers.
• Promega Corporation: Promega provides a wide range of cell-based assay reagents and bioluminescent detection technologies used in drug discovery, including GPCR and signaling pathway assays. It competes with Multispan in the assay kit and reagent market but offers a much broader product portfolio across multiple life science research areas.
• Molecular Devices (Danaher): Molecular Devices manufactures high-throughput screening instruments and cell-based assay platforms widely used in GPCR drug discovery. It is adjacent rather than directly overlapping with Multispan, but its readers and instruments are routinely paired with cell lines and assays like those Multispan supplies.
• Eurofins Pharma Discovery Services: The broader Eurofins network provides comprehensive drug discovery, safety pharmacology, and profiling services including GPCR work. It competes with Multispan's services business as part of a wider contract research platform with significantly greater global footprint.

Emerging players

• Cisbio (Revvity): Cisbio, now part of Revvity, is known for HTRF (homogeneous time-resolved fluorescence) technology used in cAMP and second messenger assays, directly comparable to Multispan's TR-FRET cAMP No Wash Assay Kit. It is a focused competitor in the assay chemistry layer that complements GPCR cell-based workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/MultispanGPCR
• YouTubeyoutube.com/@multispaninc.1378
• Facebookfacebook.com/multispangpcr
• LinkedInlinkedin.com/company/multispan-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Multispan